Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Stocks
Jubilant Pharmova Ltd.
Swot
Jubilant Pharmova Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats
Jubilant Pharmova Ltd. has 19 Strengths, 9 Weaknesses, 5 Opportunities and 2 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential
Add SWOT widget to your site/app
Strengths
(19)
Weakness
(9)
Opportunity
(5)
Threats
(2)
Others
(5)
Growth Factor Screener: Rising returns on equity (ROE), Momentum, and Earnings Yield
Benjamin Graham Value Screen
Strong Performer, Getting Expensive (DVM)
Consistent Highest Return Stocks over Five Years
Relative Outperformance versus Industry over 1 Month
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
High Momentum Scores (Technical Scores greater than 50)
Relative Outperformance versus Industry over 1 Month
Effectively using its capital to generate profit - RoCE improving in last 2 years
Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Companies with Low Debt
Companies with reducing Debt
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
Companies with Zero Promoter Pledge
Volume Shockers
Promoter decreasing their shareholding
Companies with growing costs YoY for long term projects
Promoter holding decreased by more than -2% QoQ
Negative profit growth, promoters decreasing shareholding QoQ
Degrowth in Revenue, Profits and Operating Profit Margin in recent results (QoQ)
Increasing Trend in Non-Core Income
Top Losers
Sell Zone: Stocks in the sell zone based on days traded at current PE and P/BV
Stocks Underperforming their Industry Price Change in the Quarter
Mutual Funds Increased Shareholding in Past Month
FII / FPI or Institutions increasing their shareholding
MFs increased their shareholding last quarter
Mutual Funds Increased Shareholding over the Past Two Months
Mf buying for 2 months
Sells by Superstar Investors
US FDA Warning Letter
High Piotroski Score - Companies with strong financials
Stocks with improving cash flow, with good durability
Average Affordability - Stocks with Medium Trendlyne Valuation Score versus Benchmarks
Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks
Decline in Net Profit with falling Profit Margin (QoQ)
